PMID- 37392036 OWN - NLM STAT- MEDLINE DCOM- 20230913 LR - 20230918 IS - 2398-9238 (Electronic) IS - 2398-9238 (Linking) VI - 6 IP - 5 DP - 2023 Sep TI - The LongitudinAl Nationwide stuDy on Management And Real-world outComes of diabetes in India over 3 years (LANDMARC trial). PG - e422 LID - 10.1002/edm2.422 [doi] LID - e422 AB - INTRODUCTION: LANDMARC (CTRI/2017/05/008452), a prospective, observational real-world study, evaluated the occurrence of diabetes complications, glycemic control and treatment patterns in people with type 2 diabetes mellitus (T2DM) from pan-India regions over a period of 3 years. METHODS: Participants with T2DM (>/=25 to /=2 years at the time of enrollment, with/without glycemic control and on >/=2 antidiabetic therapies) were included. The proportion of participants with macrovascular and microvascular complications, glycemic control and time to treatment adaptation over 36 months were assessed. RESULTS: Of the 6234 participants enrolled, 5273 completed 3 years follow-up. At the end of 3-years, 205 (3.3%) and 1121 (18.0%) participants reported macrovascular and microvascular complications, respectively. Nonfatal myocardial infarction (40.0%) and neuropathy (82.0%) were the most common complications. At baseline and 3-years, 25.1% (1119/4466) and 36.6% (1356/3700) of participants had HbA1c <7%, respectively. At 3-years, population with macrovascular and microvascular complications had higher proportion of participants with uncontrolled glycemia (78.2% [79/101] and 70.3% [463/659], respectively) than those without complications (61.6% [1839/2985]). Over 3-years, majority (67.7%-73.9%) of the participants were taking only OADs (biguanides [92.2%], sulfonylureas [77.2%] and DPP-IV inhibitors [62.4%]). Addition of insulin was preferred in participants who were only on OADs at baseline, and insulin use gradually increased from 25.5% to 36.7% at the end of 3 years. CONCLUSION: These 3-year trends highlight the burden of uncontrolled glycemia and cumulative diabetes-related complications, emphasizing the importance of optimizing diabetes management in India. CI - (c) 2023 Sanofi and The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd. FAU - Das, Ashok K AU - Das AK AUID- ORCID: 0000-0003-1770-1885 AD - Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeet, Puducherry, India. FAU - Kalra, Sanjay AU - Kalra S AUID- ORCID: 0000-0003-1308-121X AD - Bharti Hospital, Karnal, India. FAU - Joshi, Shashank AU - Joshi S AD - Lilavati Hospital, Mumbai, India. FAU - Mithal, Ambrish AU - Mithal A AD - Medanta- The Medicity, Gurgaon, India. FAU - Kumar, K M Prasanna AU - Kumar KMP AD - Centre for Diabetes and Endocrine Care, Bengaluru, India. FAU - Unnikrishnan, A G AU - Unnikrishnan AG AD - Chellaram Diabetes Institute, Pune, India. FAU - Thacker, Hemant AU - Thacker H AD - Bhatia Hospital, Mumbai, India. FAU - Sethi, Bipin AU - Sethi B AD - Care Hospital, Hyderabad, India. FAU - Chowdhury, Subhankar AU - Chowdhury S AD - IPGME and R and SSKM Hospital, Kolkata, India. FAU - Sugumaran, Amarnath AU - Sugumaran A AD - Sanofi, Mumbai, India. FAU - Satpathy, Ashwini AU - Satpathy A AD - Sanofi, Mumbai, India. FAU - Gadekar, Arvind AU - Gadekar A AD - Sanofi, Mumbai, India. FAU - Menon, Shalini K AU - Menon SK AD - Sanofi, Mumbai, India. FAU - Neogi, Renuka AU - Neogi R AD - Sanofi, Mumbai, India. FAU - Chodankar, Deepa AU - Chodankar D AD - Sanofi, Mumbai, India. FAU - Trivedi, Chirag AU - Trivedi C AD - Sanofi, Mumbai, India. FAU - Wangnoo, S K AU - Wangnoo SK AD - Apollo Hospital Education and Research Foundation, New Delhi, India. FAU - Zargar, A H AU - Zargar AH AD - Center for Diabetes & Endocrine Care, Srinagar, India. FAU - Rais, Nadeem AU - Rais N AD - Chowpatti Medical Centre, Mumbai, India. CN - LANDMARC study group LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20230701 PL - England TA - Endocrinol Diabetes Metab JT - Endocrinology, diabetes & metabolism JID - 101732442 RN - 0 (Blood Glucose) RN - 0 (Glycated Hemoglobin) RN - 0 (Insulin) SB - IM MH - Humans MH - Middle Aged MH - Blood Glucose MH - *Diabetes Complications/epidemiology/complications MH - *Diabetes Mellitus, Type 2/drug therapy/epidemiology/complications MH - Glycated Hemoglobin MH - Insulin/therapeutic use MH - Prospective Studies MH - Adult PMC - PMC10495555 OTO - NOTNLM OT - India OT - LANDMARC OT - T2DM OT - diabetes-related complications OT - glycemic control OT - real-world evidence OT - treatment pattern COIS- AKD, AM, AGU and NR received honoraria from Sanofi and other pharmaceutical companies. KMPK is on the advisory board of Sanofi and received honorarium for his talks. SJ received speaker/advisory/research grants from Abbott, AstraZeneca, Biocon, Boehringer Ingelheim (BI), Eli Lilly, Franco Indian, Glenmark, Lupin, Marico, MSD, Novartis, Novo Nordisk, Roche, Sanofi, Serdia, Twinhealth and Zydus. SK received honoraria/speaker fees from Eli Lilly, Novo Nordisk and Sanofi. HT received honoraria from MSD, Novartis, Sanofi and from other companies for advice and lectures. BS received honorarium from Aventis, Novo Nordisk, Eli Lilly, BI and MSD. SC received honoraria/grants from Biocon, BI, Intas, Novartis, Sanofi and Serdia. SKW has nothing to declare. AHZ received honoraria from Novo Nordisk, Eli Lilly, Johnson & Johnson, AstraZeneca, BI and Sanofi. SKM, AG, ASugumaran, ASatpathy, RN, DC and CT are/were employees of Sanofi and may hold stock options. EDAT- 2023/07/01 11:42 MHDA- 2023/09/13 06:41 PMCR- 2023/07/01 CRDT- 2023/07/01 03:14 PHST- 2023/03/22 00:00 [revised] PHST- 2023/01/24 00:00 [received] PHST- 2023/03/25 00:00 [accepted] PHST- 2023/09/13 06:41 [medline] PHST- 2023/07/01 11:42 [pubmed] PHST- 2023/07/01 03:14 [entrez] PHST- 2023/07/01 00:00 [pmc-release] AID - EDM2422 [pii] AID - 10.1002/edm2.422 [doi] PST - ppublish SO - Endocrinol Diabetes Metab. 2023 Sep;6(5):e422. doi: 10.1002/edm2.422. Epub 2023 Jul 1.